In order to test whether Olig2 SUMOylation plays a role in TMZ resistance of glioma, we employed human GBM U87-MG cells which endogenously express WT p53 but not Olig2 (Fig. S1B) [21, 34]. The gene discussed is TP53; the disease is central nervous system cancer.